hnRNPK-IN-1 - 97%, high purity , CAS No.2313528-04-8

  • ≥97%
Item Number
H648548
Grouped product items
SKUSizeAvailabilityPrice Qty
H648548-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$550.90
H648548-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$880.90
H648548-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,800.90
H648548-50mg
50mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$3,000.90
H648548-100mg
100mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$4,600.90
View related series
Apoptosis c-Myc

Basic Description

Specifications & Purity≥97%
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
Product Description

hnRNPK-IN-1 is a heterogeneous nuclear ribonucleoprotein K (hnRNPK) binding ligand with K d values of 4.6 μM and 2.6 μM measured with SPR and MST, respectively. hnRNPK-IN-1 inhibits c-myc transcription by disrupting the binding of hnRNPK and c-myc promoter. hnRNPK-IN-1 induces Hela cells apoptosis and has strongly anti-tumor activities

In Vitro

hnRNPK-IN-1 (Compound 25; 1.25-5 μM; 24 hours) treatment induces Hela cells apoptosis could be due to its repression of cmyc transcription. hnRNPK-IN-1 (1.25-5 μM; 48 hours) treatment down-regulates c-myc gene transcription and expression in Hela cells in a dose-dependent manner. hnRNPK-IN-1 shows a selective anti-proliferative effect on human cancer cell lines (Siha, A549, Hela, U2OS, A375, HuH7 and HEK293 cells) with IC50 values ranged from 1.36 to 3.59 μM. hnRNPK-IN-1 could selectively bind to hnRNP K without significant interaction with c-myc promoter DNA. The binding of hnRNPK-IN-1 to hnRNP K could disrupt the interaction between hnRNP K and c-myc promoter DNA in vitro and in cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis AnalysisCell Line: Hela cells Concentration: 1.25 μM, 2.5 μM, 5 μM Incubation Time: 24 hours Result: Induced Hela cells apoptosis and apoptosis-related protein expressions. RT-PCRCell Line: Hela cells Concentration: 1.25 μM, 2.5 μM, 5 μM Incubation Time: 48 hours Result: Caused a reduction of c-myc mRNA in a dose-dependent manner in Hela cells. Western Blot AnalysisCell Line: Hela cells Concentration: 1.25 μM, 2.5 μM, 5 μM Incubation Time: 48 hours Result: The expression levels of c-MYC also decreased in a dose-dependent manner.

In Vivo

hnRNPK-IN-1 (Compound 25; 6.7-20 mg/kg; i.p.; once a day; for three weeks) exhibits good tumor growth inhibition in a Hela xenograft tumor model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BALB/c female nude mice (five weeks old) bearing Hela cells Dosage: 6.7 mg/kg, 20 mg/kg Administration: Intraperitoneal injection; once a day; for three weeks Result: Inhibited tumor growth in a Hela cervical xenograft.

Form:Solid

IC50& Target:Kd: 4.6 μM (hnRNPK,SPR assay) and 2.6 μM (hnRNPK,MST assay)

Names and Identifiers

Canonical SMILES O=C(C1=CC=C(OC)C=C1)/C=C/C2=NC3=CC=C([N+]([O-])=O)C=C3C(N4CCOCC4)=C2
Molecular Weight 419.43

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Chemical and Physical Properties

SolubilityDMSO : 5 mg/mL (11.92 mM; ultrasonic and warming and heat to 80°C)

Related Documents

Solution Calculators